Brief: Immix Biopharma Awarded European Union Orphan Drug Designation For Nxc-201 In Al Amyloidosis
07/02/2024 15:32
Feb 7 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA AWARDED EUROPEAN UNION ORPHAN DRUG
DESIGNATION
FOR NXC-201 IN AL AMYLOIDOSIS
* IMMIX BIOPHARMA INC - 10 YEARS OF MARKET EXCLUSIVITY ONCE
AUTHORIZED IN EU
* IMMIX BIOPHARMA INC - REDUCED FEES FOR EU PROTOCOL
ASSISTANCE,
MARKETING AUTHORIZATION
* IMMIX BIOPHARMA INC - ACCESS TO EU CENTRALIZED
AUTHORIZATION
PROCEDURE
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary